NARA Discovery
Article Details
← Back to Search Results
Journal Article

Comparative Neuroprotective Potential of Nanoformulated and Free Resveratrol Against Cuprizone-Induced Demyelination in Rats

Sara A. M. El-Sayed; Ghadha Ibrahim Fouad; Maha Z. Rizk; Hanan H. Beherei; Mostafa Mabrouk
Molecular Neurobiology · Vol. 62, Issue 3 · pp. 2710-2725 · 2025

Abstract

Demyelination is a frequent yet crippling neurological disease associated with multiple sclerosis (MS). The cuprizone (CZ) model, which causes demyelination through oxidative stress and neuroinflammation, is a popular tool used by researchers to examine this process. The polyphenol resveratrol (RESV) has become a promising neuroprotective agent in seeking for efficient therapies. In a rat model given CZ, we created and examined iron oxide nanoparticles (IONPs) loaded with RESV (IONP-RESV) to see how effective they were as a therapeutic agent against free RESV. According to molecular mechanisms, exposure to CZ resulted in a marked downregulation of myelin proteolipid protein (PLP) expression and an overexpression of the inflammatory markers tumor necrosis factor-α (TNF-α) and S100β, which are indicators of demyelination and neuroinflammation. It is remarkable that these CZ-induced alterations could be reversed by therapy with either RESV or IONP-RESV. Interestingly, IONP-RESV showed even stronger anti-inflammatory activity, as shown by a more noticeable downregulation of TNF-α and S100β expression. These results were confirmed by histopathological examination of the cerebral cortices. Our findings support the better neuroprotective benefits of RESV-loaded IONPs over free RESV in reducing demyelination and neuroinflammation brought on by CZ. Owing to their pro-remyelinating, anti-inflammatory, and antioxidant properties, RESV-loaded IONPs show promise as a neurotherapeutic intervention in the future for neurological diseases such as multiple sclerosis. Graphical Abstract

Bibliographic Information

JournalMolecular Neurobiology
PublisherSpringer
Publication Date2025-03-01
Publication Year2025
Volume62
Issue3
Pages2710-2725
Document TypeJournal Article
Print ISSN0893-7648
eISSN1559-1182
DOI10.1007/s12035-024-04415-x

Access Information

NARA Access Coverage1987-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12035
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.